TABLE 1.
RT amino acid substitutions in patients with reduced NNRTI or ZDV susceptibility
| Patient sample | EC50 FC results obtained using RH/IN RTVsa |
|||
|---|---|---|---|---|
| DLV | EFV | NVP | ZDV | |
| 396b,c | 2.8 | 3.3 | 5.0 | 3.2 |
| 471b,c | 2.9 | 1.8 | 5.9 | 2.8 |
| 440b,c | 3.1 | 2.3 | 5.9 | 3.3 |
| 62b | 3.4 | 1.8 | 7.6 | 1.3 |
| 477b,c | 4.5 | 2.8 | 11.0 | 1.9 |
| 384b,c | 6.7 | 4.2 | 11.0 | 3.0 |
| 429c | 1.1 | 1.3 | 1.2 | 2.1 |
| 58c | 1.5 | 0.9 | 1.7 | 2.3 |
| 138c | 1.7 | 1.1 | 1.8 | 2.0 |
| 87c | 1.3 | 1.3 | 1.9 | 2.1 |
| 474c | 1.6 | 1.3 | 3.0 | 2.1 |
| 249c | 1.3 | 1.3 | 3.1 | 2.0 |
| 439c | 3.1 | 2.7 | 3.7 | 2.2 |
| 442c | 2.6 | 2.0 | 4.0 | 3.5 |
a
Values in boldface indicate FC results above the biological cutoffs for the corresponding drugs.
b
Patient with reduced susceptibility to DLV, EFV, or NVP.
c
Patient with reduced susceptibility to ZDV.